UBS Group AG Boosts Stake in Nurix Therapeutics, Inc. $NRIX

UBS Group AG raised its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 16.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 423,425 shares of the company’s stock after purchasing an additional 60,879 shares during the quarter. UBS Group AG owned 0.55% of Nurix Therapeutics worth $8,032,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wexford Capital LP purchased a new stake in shares of Nurix Therapeutics in the 3rd quarter valued at $41,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Nurix Therapeutics by 66.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,926 shares of the company’s stock valued at $93,000 after buying an additional 1,970 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Nurix Therapeutics by 118.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock valued at $73,000 after buying an additional 3,475 shares during the period. Sherbrooke Park Advisers LLC purchased a new stake in shares of Nurix Therapeutics in the 3rd quarter valued at $100,000. Finally, 49 Wealth Management LLC purchased a new stake in shares of Nurix Therapeutics in the 3rd quarter valued at $108,000.

Wall Street Analysts Forecast Growth

NRIX has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $32.00 price objective on shares of Nurix Therapeutics in a report on Monday, April 27th. Stifel Nicolaus boosted their price objective on Nurix Therapeutics from $33.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, January 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Tuesday, April 21st. BTIG Research reiterated a “buy” rating and issued a $30.00 price objective on shares of Nurix Therapeutics in a report on Monday. Finally, Royal Bank Of Canada upped their price target on Nurix Therapeutics from $28.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Nurix Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $30.46.

Nurix Therapeutics Stock Performance

NASDAQ:NRIX opened at $15.51 on Tuesday. The stock has a 50-day simple moving average of $15.91 and a 200-day simple moving average of $16.47. The stock has a market cap of $1.60 billion, a P/E ratio of -4.91 and a beta of 1.87. Nurix Therapeutics, Inc. has a 1 year low of $8.19 and a 1 year high of $22.50.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Wednesday, April 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.03). The business had revenue of $6.25 million for the quarter, compared to analyst estimates of $14.25 million. Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%. On average, equities research analysts predict that Nurix Therapeutics, Inc. will post -2.94 EPS for the current year.

Insider Activity

In related news, insider Gwenn Hansen sold 3,214 shares of the company’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $16.65, for a total value of $53,513.10. Following the completion of the sale, the insider directly owned 120,399 shares of the company’s stock, valued at $2,004,643.35. This represents a 2.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Houte Hans Van sold 14,055 shares of the company’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total value of $233,313.00. Following the completion of the sale, the chief financial officer directly owned 37,592 shares of the company’s stock, valued at approximately $624,027.20. This trade represents a 27.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 19,657 shares of company stock valued at $326,586. Insiders own 6.70% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.